Podcast appearances and mentions of ashley mcevoy

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new Austrailian study aims to prevent type 1, the new twiist pump will integrate with Eversnse CGM as well as Libre, diabetes deaths are down in the US, Dexcom U is looking for college athletes, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A world-first human trial of a drug designed to treat the underlying cause of type 1 diabetes has begun in Australia. University of Queensland researcher Ranjeny Thomas said the experimental drug — dubbed ASITI-201 — was designed to retrain the immune system so it no longer attacks the insulin-producing pancreatic cells, known as beta cells. The drug, given as an injection under the skin, combines fragments of a protein found in the beta cells of people with type 1 diabetes and vitamin D to calm the immune response. She said if effective, the drug would initially be given to patients with type 1 diabetes as soon as possible after diagnosis to preserve remaining pancreatic cells and reduce the amount of insulin needed. But eventually, if screening programs can be developed to pick up people at risk of developing type 1 diabetes, it may be possible to "prevent the progression of the disease altogether". The first in-human trial of 36 participants will test the safety of the drug, but blood tests will also determine the impact of the therapy on a patient's immune system and glucose tolerance. https://www.abc.net.au/news/2025-04-29/type-1-diabetes-drug-trial-auto-immune-disease-science/105223022 XX   Diabetes deaths in the U.S. have fallen to some of the lowest rates in years, according to new preliminary figures published by the Centers for Disease Control and Prevention, reversing a surge in mortality that was seen during the COVID-19 pandemic.   There were 26.4 deaths per 100,000 people from diabetes, according to early death certificate data for the third quarter of 2024 published this month by the CDC's National Center for Health Statistics.   Death rates from diabetes peaked in 2021, according to CDC figures, at 31.1 deaths per 100,000 people for that year. Diabetes was the eighth leading cause of death in 2021. The CDC says the link between COVID-19 and diabetes may be to blame for that increase.   "Data show an increase in mortality rates for all people during the COVID-19 pandemic, and research shows that people with underlying conditions, including diabetes, are more likely to become very sick from COVID-19 and have a higher risk of hospitalization and death," Christopher Holliday, head of the CDC's Division of Diabetes Translation, told CBS News in a statement.   Holliday added that research shows the pandemic may also have made it harder for Americans to properly manage the disease, ranging from interruptions to physical activity to disruptions to routine medical care diagnosing and treating the disease.   https://www.cbsnews.com/news/diabetes-deaths-lowest-levels-years-early-cdc-figures/ XX Big news for the Eversense CGM – they have their first pump partner. Sequel Med Tech says the twist pump will integrate with Senseonics Eversense 365 continuous glucose monitor (CGM). This collaboration would make twiist the first AID system compatible with Eversense 365, the world's first and only one-year CGM. Sequel and Senseonics say they have already started their work to integrate the latest-generation, 365-day implantable sensor with twiist. They expect to make the integrated offering available in the third quarter of this year. This marks the second CGM integration for Sequel, which partnered with Abbott and its FreeStyle Libre platform earlier this year. This week we also got a peek at the packaging and delivery of the twist as the first people posted about wearing it. We'll follow up and learn more about this newest insulin pump in the us. Senseonics, meanwhile, brought the first year-long CGM to market last year, launching Eversense 365 with its global distribution partner, Ascensia Diabetes Care, in October 2024. The system also received clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems. https://www.drugdeliverybusiness.com/sequel-senseonics-integrate-cgm-insulin-pump/ XX Medtronic has announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync sensor for use with the MiniMed 780G system. With this approval, the MiniMed 780G system now offers more flexibility for users of the company's most advanced insulin delivery system featuring Meal Detection technology with both the Guardian 4 sensor and Simplera Sync sensor.   The Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard or overtape and features a simple, two-step insertion process. It is the company's newest addition to its CGM portfolio, which expands options and provides greater flexibility for users.   The MiniMed 780G system's adaptive algorithm automatically anticipates, adjusts, and corrects glucose levels every 5 minutes, 24/7 – working around the clock so users can focus on what matters. It's the only system featuring Meal Detection technology, which detects rising sugar levels and delivers more insulin as needed to help users keep glucose levels in range more often – even when users occasionally forget to dose insulin for snacks or meals or underestimate their carbs.   The system uses a “treat to target” approach and flexible glucose targets as low as 100 mg/dL, which, combined with its adaptive algorithm allows it to more closely mirror the glucose levels of someone not living with diabetes.   Real-world data of the system shows global users consistently achieve time in range above international targets of 70% when using optimal settings (active insulin time of two hours and 100 mg/dL target glucose). It is also the only system that works with the world's only infusion set that lasts up to 7 days so that users only have to change their infusion set once per week and can experience 96% fewer injections compared to multiple daily injections.   “We're committed to driving innovation that makes life easier for those living with diabetes so they can forget about their diabetes as much as possible throughout the day,” said Que Dallara, EVP and president of Medtronic Diabetes. “Our MiniMed 780G system delivers advanced diabetes technology for so many around the world, and we're excited to continue evolving this experience with expanded CGM options —including our Simplera Sync sensor, which we look forward to bringing to people living with diabetes in the U.S.”   A limited launch of the Simplera Sync sensor will begin in the U.S. in the fall of 2025. Today, the MiniMed 780G system can be used with the Guardian 4 sensor.   Like this:https://med-techinsights.com/2025/04/29/simplera-sync-sensor-for-minimed-780g-now-fda-approved/ XX Front office changes at Insulet.. The former head of Johnson & Johnson's worldwide medtech business, Ashley McEvoy will take over as president and CEO from Jim Hollingshead, who has led Insulet since 2022. In its announcement of the leadership change, Insulet said that Hollingshead and the company mutually agreed to part ways, effective immediately. McEvoy served as worldwide medtech chairman at J&J from 2018 until her departure in late 2023, the culmination of nearly 30 years at the company and several executive roles—including president of its Ethicon division and group chairman of vision and diabetes care. Since then, she has also served as a board member at Procter & Gamble. https://www.fiercebiotech.com/medtech/insulet-taps-former-jj-medtech-head-ashley-mcevoy-be-ceo XX New free mobile game launched this week to make type 1 diabetes onboarding faster easier and less overwhelming. It's called Level One.. created by Level Ex (Powered by Relevate Health), the studio behind award-winning medical games for medical professionals. Level Ex CEO Sam Glassenberg created the game after a – quote  - brutal onboarding experience when his daughter was diagnosed five years ago He says  It took a year to understand how to manage this disease. So we fixed it. We built a game that can train your brain to do it in a matter of hours." The game is launching in partnership with leading diabetes organizations Beyond Type 1 and Breakthrough T1D Play, who are integrating Level One into their outreach and educational campaigns to support newly diagnosed families worldwide. Download Level One on the App Store: https://apps.apple.com/us/app/level-one-a-diabetes-game/id6739605694 Learn more: https://playlevelone.com   https://www.prnewswire.com/news-releases/level-ex-launches-level-one-a-free-mobile-game-to-redefine-type-1-diabetes-onboarding-302440929.html XX   Collagen is widely recognized for its role in maintaining healthy skin, but its importance extends far beyond that. As the most abundant protein in the human body, collagen provides essential structure and support to nearly all tissues and organs.   Now, researchers at Carnegie Mellon's Feinberg Lab have made a major breakthrough using their novel Freeform Reversible Embedding of Suspended Hydrogels (FRESH) 3D bioprinting technique. This method enables the precise printing of soft, living cells and tissues. Leveraging this technology, the team successfully created the first-ever microphysiologic system, also known as a tissue model, constructed entirely from collagen. This advancement opens new possibilities for studying disease and engineering tissue therapies, including potential treatments for conditions like Type 1 diabetes.   Traditionally, small-scale models of human tissue, referred to as microfluidics, organ-on-chip devices, or microphysiologic systems, have been fabricated using synthetic materials such as silicone rubber or plastics. These materials were necessary due to limitations in earlier manufacturing techniques. However, because they are not biologically native, they fail to fully replicate natural tissue environments, restricting their effectiveness in biomedical research and therapeutic development.   “Now, we can build microfluidic systems in the Petri dish entirely out of collagen, cells, and other proteins, with unprecedented structural resolution and fidelity,” explained Adam Feinberg, a professor of biomedical engineering and materials science & engineering at Carnegie Mellon University. “Most importantly, these models are fully biologic, which means cells function better.”   Building Complex Tissues with FRESH Bioprinting In new research published in Science Advances, the group demonstrates the use of this FRESH bioprinting advancement, building more complex vascularized tissues out of fully biologic materials, to create a pancreatic-like tissue that could potentially be used in the future to treat Type 1 diabetes. This advancement in FRESH bioprinting builds on the team's earlier work published in Science, by improving the resolution and quality to create fluidic channels that are like blood vessels down to about 100-micron diameter.   “There were several key technical developments to the FRESH printing technology that enabled this work,” described Daniel Shiwarski, assistant professor of bioengineering at the University of Pittsburgh and prior postdoctoral fellow in the Feinberg lab. “By implementing a single-step bioprinting fabrication process, we manufactured collagen-based perfusable CHIPS in a wide range of designs that exceed the resolution and printed fidelity of any other known bioprinting approach to date. Further, when combined with multi-material 3D bioprinting of ECM proteins, growth factors, and cell-laden bioinks and integration into a custom bioreactor platform, we were able to create a centimeter-scale pancreatic-like tissue construct capable of producing glucose-stimulated insulin release exceeding current organoid based approaches.” https://scitechdaily.com/scientists-bioprint-living-tissues-that-could-revolutionize-diabetes-treatment/ XX Another study showing the blood sugar benefit of walking after a meal. Skeletal muscle plays a central role in glucose uptake. Exercise stimulates glucose transport into muscle cells through insulin-independent pathways, notably through the action of glucose transporter type 4 (GLUT-4), which is responsible for transporting glucose from blood to skeletal muscles.4 This means that even without a robust insulin response, physical activity can facilitate glucose clearance from the bloodstream. These effects also occur without requiring high-intensity exercise, making postprandial walking accessible to a broad range of individuals, including those with limited exercise tolerance. multiple studies show that starting activity within 30 minutes after a meal is optimal. https://www.news-medical.net/health/Walking-After-Meals-Small-Habit-Big-Metabolic-Gains.aspx XX Dexcom brings back Dexcom U for a 4th years. This is a name, image and license program for college athletes with diabetes and includes a nationwide open call for passionate and inspiring college athletes to join its roster. Now through May 23, athletes, coaches, friends and family members can nominate candidates through an online submission. Those selected, along with the eight returning athletes from last year, will be invited to attend the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. https://www.hmenews.com/article/dexcom-u-returns-for-fourth-season

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, December 14, 2023. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast. Ekso Bionics announced it earned a Medicare win for its exoskeleton technology this week. Fast Five hosts Sean Whooley and Danielle Kirsh discuss what the win means for the company and the technology it is developing.  Calyxo closed a $50 million funding round to support kidney stone treatment. Hear how much funding the company has received in recent years and what the company's technology does. Tandem Diabetes Care has launched its diabetes management platform for insulin pump users. Whooley talks about what the new platform is designed for and some other positive news from the company in recent months.  Former Johnson & Johnson MedTech head Ashley McEvoy has landed a board position at a consumer goods giant. Learn where she is joining the board in today's episode.  Integra LifeSciences is buying J&J's Acclarent and its ENT technology. Whooley and Kirsh discuss the financial details of the deal and how it will supplement Integra LifeSciences' portfolio.

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, October 25, 2023. Check out the show notes for links to the stories we discuss today at MassDevice.com/podcast. The first commercial cases using Levita Magnetics' surgical robot were recently announced. Fast Five hosts Sean Whooley and Danielle Kirsh detail what the surgical robot does and what doctors think about the robot. Moon Surgical also announced the first commercial cases in France of its Maestro surgical robot. Hear what procedures it was used in and what surgeons thought about its use.  Butterfly Network is looking to make a move in the BCI space. Whooley talks about the company's latest partnership to boost the use in brain-computer interfaces and what executives think. The 3M Health Care spinoff is on track to be completed in early 2024. The Fast Five hosts discuss the optimism 3M executives have with the progress of the spinoff, as well as some of the executive appointments that have already been announced. Johnson & Johnson MedTech chair Ashley McEvoy announced she is stepping down to pursue other opportunities. Hear more about her incredible career at J&J, who is taking her place and the parting words she shared on her time at J&J.

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. Today, we have several key developments to discuss in the medical technology industry. Let's dive in.First, Danaher's Q3 revenue has declined due to ongoing demand challenges, but respiratory testing revenue has been a bright spot. The FDA has also updated its list of cleared AI/ML medical devices, adding 171 new devices primarily in radiology. Activist investor Carl Icahn is suing Illumina, seeking to remove board members and claiming damages over their handling of the acquisition of Grail. In addition, Olympus has issued a recall of its abdominal insufflation devices after reports of patient injuries and one death. Ashley McEvoy is stepping down as the chairman of J&J's medtech business, with Tim Schmid taking over. Small- and medium-sized medtech companies are facing challenges under the EU Medical Device Regulation. Moving on to payer news, Centene Corporation has beaten Q3 forecasts despite pressure from Medicare Advantage star ratings and redeterminations. HCA Healthcare, on the other hand, missed Q3 expectations due to costs associated with its physician staffing firm, Valesco. A report by the Robert Wood Johnson Foundation and the Urban Institute found that if the 10 remaining states expanded Medicaid, 2.3 million people would gain coverage. Prospect Medical Holdings has been given clearance to seek a buyer for its struggling four-hospital health system, Crozer Health. Kaiser Permanente imaging services workers will join an ongoing strike among pharmacy workers in Oregon and Washington. Independent pharmacies are suing Express Scripts over alleged price fixing.In the biotech world, Orbimed has raised $4.3 billion in new funds for startup investing. Novartis has delayed its FDA filing for its radiopharma drug Pluvicto due to mixed survival data. Aiolos Bio has raised $245 million for a better asthma drug targeting an inflammation-linked protein. Rampart Biosciences, an Orbimed-backed biotech, has launched with $85 million to develop a new kind of DNA medicine. Seagen's trial data at ESMO impressed, boosting stock prices for Merck and Pfizer. Roche's planned buyout of Telavant has pushed 2023's deal value total above $100 billion. PRC Clinical is partnering with TrialHub to transform the clinical research landscape, and Novo Nordisk is facing weight problems with its drug Ozempic.Moving on to Swiss pharmaceutical company Novartis, they reported a 12% increase in sales and 21% growth in core operating income for Q3. Verve Therapeutics received FDA approval for its first in-human base editing study in the US. Belgium is considering a short-term ban on Novo Nordisk's Ozempic for weight loss due to supply constraints. AstraZeneca and Daiichi Sankyo addressed safety concerns for their investigational antibody-drug conjugate candidate at the ESMO conference.Next, we have Pfizer's vaccine business, which has experienced significant growth driven by the success of its COVID-19 vaccine, Comirnaty. Pfizer is expanding its vaccine portfolio with new approvals. The recipients of the 2023 Red Jackets will be announced during a virtual event called "The Next Frontier of the Life Sciences." Other news includes the CDC updating recommendations for the RSV shot, AstraZeneca's cancer drug allaying safety concerns but still facing questions, Roche settling a US patent lawsuit against Biogen, and Wall Street increasing forecasts for anti-obesity drug sales.In funding news, Rampart Biosciences has raised $85 million to develop more potent DNA-based medicines. Invea Therapeutics and Cargo Therapeutics have joined the IPO queue, and Laronde is merging with Senda Biosciences. Ultragenyx plans to spin out a new company focused on Alzheimer's gene therapy. Roche has agreed to acquire Televant for $7.1 billion.That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more important new

What's life really like at the top of a $30 billion healthcare company? While many might find the prospect of serving 300 million patients around the world daunting, Ashley McEvoy, Worldwide Chairman of Johnson & Johnson MedTech, sees it as a privilege. While at the helm of J&J MedTech, her impact has been significant: she has tripled its revenue growth since 2017 and spearheaded its entrance into telehealth, robotics, and digital surgery. At a time when senior executive tenure is often short, Ashley has carved out a career at J&J MedTech spanning almost three decades—all while maintaining an unwavering passion for providing the very best care to patients when they need it most. In this fascinating episode of Redefiners, Ashley lifts the lid on how J&J MedTech is transforming how it delivers care to patients with the help of AI, why being an exceptional listener should be in every leader's toolbox, and why your inner voice is the most powerful voice of anyone in the world. It's a conversation you don't want to miss. We'll also hear from Fawad Bajwa, a Managing Director in our Toronto office. He'll outline how generative AI tools like ChatGPT are changing the game for leaders, and how great leadership is critical to its successful implementation. Click HERE to access our report How will ChatGPT and other generative AI impact leadership? If you enjoyed this interview, you might also like these Redefiners episodes:• Risk-taking and Dealmaking with Global MedTech Leader, Kevin Lobo• Confessions of a Serial Entrepreneur with Mario Schlosser, CEO and co-founder of Oscar• Break the Bias: Closing the Gender Wealth Gap with Sallie Krawcheck, CEO and c-founder of Ellevest 

Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices, at Johnson & Johnson recently joined AdvaMed's Scott Whitaker to discuss her views on leadership, her work with the Trevor Project, and her role as chair of the AdvaMed committee tasked with addressing head-on the issue of racial disparities in health care access and outcomes.

HAPPY BIG 5-0!! This week’s is our 50th DeviceTalks Weekly Podcast, and we’re going to celebrate! Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices, Johnson & Johnson, makes her DeviceTalks Weekly debut. In this update, McEvoy delivers great insights on several areas of interest including: • COVID-19’s impact on J&J in the past, and what changes may remain in the future. • J&J’s far-ranging digital surgery portfolio could bolster many of its specialties. • How the company uses its innovation network to accelerate development • Why she’s bullish on the future of eye care. • How the company will prepare for future challenges. We also talk with Naomi Murray, Director of Advanced Operations-Additive Technology at Stryker about her almost predestined path to join the orthopedics leader. She’ll be leading the March 23 discussion on Additive Manufacturing at DeviceTalks Tuesday. Register at DeviceTalks.com. Colleague Lisa Eitel, executive editor of Design World, crashes the party to tell us about her upcoming Women in Engineering webcast. Register for that discussion at https://www.designworldonline.com/design-world-online-events-and-webinars/ Finally, Chris Newmarker delivers some good news and bad Newmarker's Newsmakers from the digital pages of MassDevice, Medical Design & Outsourcing, and other sites. Companies highlighted include Frequency, Medtronic, Theranos, GE Healthcare, DJO and Stryker Subscribe now on any major podcast channel. Google. Apple. Spotify. Amazon, etc.

Welcome to the My WHIM Life show where it is our mission is to create a significant impact in this world by sharing WISDOM, HUMOR, INSPIRATION & MOTIVATION in such a way that YOU will use it to affect actual real change in your own life and the lives of others creating a ripple effect of goodness!This week's guest is Ashley McEvoy! Ashley is an independent distributor of Plexus Worldwide, a bartender at a local restaurant AND a mom of SEVEN kids!! She really does it all!Please help me welcome, Ashley.Contact Ashley at: ashymack87@gmail.comAshley’s Fun Facts:Q: What was your first word? A: NoQ: School achievements?A: I won the race to read

This show is the real deal. I honestly almost edited the first five minutes because the "flow" was not happening yet. However, my beautiful guest Ashley McEvoy reminded me of being genuine, about being authentic. You might see me stumbling over words, repeating a few things- but that is life right? So I kept it.  It is definitely in line with Ashley's journey. She stumbled a bit at the beginning of life- made some challenging choices and felt innately flawed for so many years of her life. During one of her darkest periods in life- she discovered the answer to her healing and the things that catapulted her to her great success in life. She will share her story and shed light on exactly how she climbed out of the dark hole in her life and learned to find joy regardless of circumstances.  This is a special episode. You are going to fall in love with the magnificent Ashley McEvoy.    

Last week, Johnson & Johnson announced plans to acquire TearScience, maker of a line of products capable of diagnosing and treating Meibomian gland dysfunction, a leading cause of Dry Eye. Ashley McEvoy , Company Group Chairman for Johnson & Johnson Vision, explains where TearScience will fit into J&J if the deal is completed and what the global giant’s plans for additional Dry Eye treatments may be.

Ashley McEvoy, group chairman of J&J’s Vision Group, says the combination of consumer and surgical businesses will create a powerful new force in ophthalmology.

Ashley McEvoy, Company Group Chairman, Johnson & Johnson Vision Care and Johnson & Johnson Diabetes Care Companies, says the new force could pursue M&A in future expansion. Hear the details of the deal.

At the recent Ophthalmology Innovation Summit in Chicago, Jeff George, Presi-dent & Global Head of Alcon; David E.I. Pyott, CEO of Allergan; Murthy V. Simhambhatla, PhD, President of Abbott Medical Optics; and Ashley McEvoy, Company Group Chairman of Johnson & Johnson Vision Care shared how they balance external innovation with the acquisition of out-side technologies to further the ophthalmic franchises.